TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Royal Philips
Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

A global clinical trial revealed that treating additional narrowed arteries during the first heart attack procedure is as safe and effective as waiting for a follow-up procedure, offering more personalized treatment options for patients.

Insights
PHG   positive

The company's technology was central to the clinical trial, demonstrating the effectiveness of their physiological assessment tools and supporting the generation of robust medical evidence